2-Chloro-3-substituted-1,4-naphthoquinone inactivators of human cytomegalovirus protease

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 19, 1999, Pages 2863-2866

  Ertl, Peter ^a   Cooper, David ^a   Allen, Geoffrey ^a   Slater, Martin J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CYTOMEGALOVIRUS INFECTION; DRUG INHIBITION; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN CYTOMEGALOVIRUS; PROTEINASE INHIBITION;

BINDING SITES; CELL LINE; CYSTEINE; GLUTATHIONE; HUMANS; LEUKOCYTE ELASTASE; MOLECULAR STRUCTURE; NAPHTHOQUINONES; PLAQUE ASSAY; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; THROMBIN;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; RNA VIRUSES;

EID: 0033523638     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00489-8     Document Type: Article

References (23)

1. 1. Myers, J.D.; Flournoy, N.; Thomas, E.D. J. Infect. Dis. 1986, 153, 478
2. 2. Glenn J. Rev. Infect Dis. 1981, 3, 1151.
3. 3. Jacobsen, M.A.; Mills J. Ann. Intern Med. 1988, 108, 585.
4. 4. Heinemann, M.H. J. Am. Med. 1992, 92, 12S.
5. 5. Gibson, W.; Welch, A.R.; Hall, M.R.T. Perspect. Drug. Discov. Design 1994, 2, 413.
6. 6. Holwerda, B.C. Antiviral Res. 1997, 35, 1.
7. 7. Chen, P.; Tsuge, H.; Almassey, R.J.; Gribskov, C.L.; Katoh, S.; Vanderpool, D.L.; Marbosiak, S.A.; Pinko, C.; Matthews, D.A.; Kan, C.C. Cell 1996, 86, 835.
8. 8. Tong, L.; Quian, C, G.; Massariol, M.J.; Bonneau, P.R.; Cordingley, M.G.; LaGace, L.A. Nature 1996, 383, 272.
9. 9. Qui, X.Y.; Gulp, J.S.; Dilella, A.G.; Hellmig, B.; Hoog, S.S.; Janson, C.A.; Smith, W.W.; Abdelmeguid, S.S. Nature 1996, 383, 275.
10. 10. Shieh, H.S.; Kurumbail, R.G.; Stevens, A.M.; Stegeman, R.A.; Sturman, E.J.; Pak, J.Y.; Wittwer, A.J.; Palmier, M.O.; Wiegand, R.C.; Holwerda, B.C.; Stallings, W.C. Nature 1996, 383, 279.
11. 11. Ogilvie, W.; Bailey, M.; Poupart, M-A.; Abraham, A.; Bhavsar, A.; Bonneau, P.; Bordeleau, J.; Bousquet, Y.; Chabot, C.; Duceppe, J-S.; Fazal, G.; Goulet, S.; Grand-Maître, C.; Guse, I; Halmos, T.; Lavellée, P.; Leach, M.; Malenfant, E.; O'Meara, J.; Plante, R.; Plouffe, C.; Poirer, M.; Soucy, F.; Yoakim, Y.; Dèziel, R. J. Med. Chem. 1997, 40, 4113.
12. 12. LaFemina, R.L.; Bakshi, K.; Long, W.J.; Pramanik, B.; Veloski, C.A.; Wolanski, B.S.; Marcy, A.I.; Hazuda, D.J. J. Virol. 1996, 70, 4819.
13. 13. Borthwick, A.; Weingarten, G.; Haley, T.M.; Tomaszewski, M.; Wang, W.; Hu, Z.; Bedard, J.; Jin, H.; Yuen, L.; Mansour, T.S. Bioorg. Med. Chem. Lett. 1998, 8, 365.
14. 14. Yoakim, C.; Ogilvie,W.W.; Cameron, D.R.; Chabot, C.; Grand-Maître, C.; Guse, I.; Haché, B.; Kawai, S.; Naud, J.; O'Meara, J.A.; Plante, R.; Déziel, R. Antiviral Chem. Chemotherapy 1998, 9, 379.
15. 15. Yoakim, C.; Ogilvie, W.W.; Cameron, D.R.; Chabot, C.; Guse, I.; Haché, B.; Naud, J.; O'Meara, J.A.; Plante, R.; Déziel. J. Med. Chem. 1998, 41, 2882.
16. 16. Johnstone, S.H.; Wildley, M.J.; Nygaard, J.; Jones, T.R.; Gluzman, Y. Biochemistry 1996, 35, 5838.
17. 17. Baum, E.Z.; Ding, W.D.; Siegel, M.M.; Kulmes, J.; Bebernitz, G.A.; Sridharan, L.; Tabei, K.; Krishnamurthy, G.; Carofiglio, T.; Groves, J.T.; Bloom, J.D.; Digrandi, M.; Bradley, M.; Ellestad, G.; Seddon, A.P.; Gluzman, Y. Biochemistry 1996, 35, 5847.
18. 18. Flynn, D.L. Becker, D.P.; Dilworth, V.M.; Highkin, M. K.; Hippenmeyer, P.J.; Houseman, K.A.; Levine, L.M.; Li, M.; Moorman, A.E.; Rankin, A.; Toth, M.V.; Villamil, C.I.; Wittwer, A.J.; Holwerda, B.C. Drug Des. Discovery 1997, 15, 3.
19. 3H)G, Amersham, 125Ci/mmol, 1mCi/ml). Reactions were incubated at 25 °C for 60 mins, and stopped by addition of 170 μ1 of 3mM zinc chloride containing 40 μg of streptavidin-SPA beads (Amersham NK8972). Inhibition of enzyme activity was calculated by comparison to controls.
20. 20. Compounds were prepared according to established procedures. See Boehm, P.; Cooper, K.; Hudson, A.T.; Elphick, J.P.; McHardy, N. J. Med. Chem. 1981, 24, 295. Hudson, A.T.; Pether, M.J.; Randall, A.W.; Fry, M.; Latter, V.S.; McHardy, N. Eur. J. Med. Chem. Chim. Ther. 1986, 21,271.
21. 20. Compounds were prepared according to established procedures. See Boehm, P.; Cooper, K.; Hudson, A.T.; Elphick, J.P.; McHardy, N. J. Med. Chem. 1981, 24, 295. Hudson, A.T.; Pether, M.J.; Randall, A.W.; Fry, M.; Latter, V.S.; McHardy, N. Eur. J. Med. Chem. Chim. Ther. 1986, 21,271.
22. 19 except that, after pre-incubation , substrate (peptide RGVVNASSRLAK) was added to a final concentration of 100 μM, and reactions were stopped after 60 mins by addition of 30 μ1 of 0.2% TFA in water. Samples were filtered and examined by HPLC on a C18 reverse phase column (ABI Bronlee (10×4.6) No. 0711 0021). Substrate and product peaks were determined and used to calculate the level of cleavage.
23. 22. Rahim, S.G.; Tivedi, N.T.; Bogunovic-Batchelor, M.V.; Hardy, G.W.; Mills, G.; Selway, J.W.T.; Snowden, W.; Littler, E.; Coe, P.L.; Basnak, I.; Whale, R.F.; Walker, R.T. J. Med. Chem. 1996, 39, 789.